Regeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN) is anticipated to post its Q4 2025 results before the market opens on Friday, January 30th. Analysts expect the company to announce earnings of $10.48 per share and revenue of $3.7585 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, January 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the business earned $12.46 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $755.51 on Friday. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The business’s fifty day moving average is $754.18 and its 200 day moving average is $641.57. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The firm has a market cap of $79.40 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 1.95 and a beta of 0.39.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Analyst Ratings Changes

A number of analysts recently weighed in on REGN shares. Evercore ISI upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a report on Thursday. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. HSBC assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 target price on the stock. Finally, Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $794.70.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 8,431 shares of company stock valued at $5,733,521. Corporate insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Banque Transatlantique SA raised its position in Regeneron Pharmaceuticals by 105.4% during the 2nd quarter. Banque Transatlantique SA now owns 304 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 156 shares during the last quarter. MUFG Securities EMEA plc purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $161,000. Papamarkou Wellner Asset Management inc. bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $205,000. Dynamic Technology Lab Private Ltd purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth $226,000. Finally, Larson Financial Group LLC boosted its holdings in Regeneron Pharmaceuticals by 153.1% in the third quarter. Larson Financial Group LLC now owns 448 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 271 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.